NCT04150913 2025-11-25A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated NeurotoxicityMassachusetts General HospitalPhase 2 Completed15 enrolled 17 charts
NCT04359784 2025-10-23Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell TherapyFred Hutchinson Cancer CenterPhase 2 Completed27 enrolled 15 charts